Ontology highlight
ABSTRACT:
SUBMITTER: Mbala-Kingebeni P
PROVIDER: S-EPMC7888312 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
Mbala-Kingebeni Placide P Pratt Catherine C Mutafali-Ruffin Mbusa M Pauthner Matthias G MG Bile Faustin F Nkuba-Ndaye Antoine A Black Allison A Kinganda-Lusamaki Eddy E Faye Martin M Aziza Amuri A Diagne Moussa M MM Mukadi Daniel D White Bailey B Hadfield James J Gangavarapu Karthik K Bisento Nella N Kazadi Donatien D Nsunda Bibiche B Akonga Marceline M Tshiani Olivier O Misasi John J Ploquin Aurelie A Epaso Victor V Sana-Paka Emilia E N'kasar Yannick Tutu Tshia YTT Mambu Fabrice F Edidi Francois F Matondo Meris M Bula Bula Junior J Diallo Boubacar B Keita Mory M Belizaire Marie R D MRD Fall Ibrahima S IS Yam Abdoulaye A Mulangu Sabue S Rimoin Anne W AW Salfati Elias E Torkamani Ali A Suchard Marc A MA Crozier Ian I Hensley Lisa L Rambaut Andrew A Faye Ousmane O Sall Amadou A Sullivan Nancy J NJ Bedford Trevor T Andersen Kristian G KG Wiley Michael R MR Ahuka-Mundeke Steve S Muyembe Tamfum Jean-Jacques JJ
The New England journal of medicine 20210401 13
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We i ...[more]